Breadcrumb

Asset Publisher

null HIV Immunophatology and Cellular Immunology

Description

Understanding the immunopathogenesis of HIV infection is crucial for understanding the mechanisms involved in the susceptibility/ resistance and the progression of the HIV disease. Moreover, the functional complexity of the HIV-specific immune response and the lack of an unique and reliable correlate of protection in front of the infection or the disease progression constitute serious obstacles for the development of an effective vaccine. Nowadays, there is strong evidences supporting the hyphotesis that an immune response against HIV-1, both helper (CD4 o Th) and cytotoxic (CD8 o CTL), eficient and maintained over time, are of major relevance for allowing the control of viral replication. To enhance and optimize this heterogeneous response is therefore a fundamental tool to control infection and improve the prognosis of HIV-infected patients.

Research topics of interest and ongoing projects

  • Study and evaluation of the immune response elicited by future candidates for preventative and therapeutic HIV vaccines in development.
  • Ex vivo characterization of the cellular immune response  against HIV-1 using defective viral vectors.
  • Study of mechanisms implicated in the immune activation in HIV-infected patients
  • Analysis of mucosal immunity in preventative and therapeutic strategies
  • Role of microRNAS on the regulation of efficient immune response in HIV-1-infected individuals who control infection without antiretroviral treatment.
  • Prospective study aleatorized, open and multicentric: Antiretroviral treatment once a day in naïve HIV-infected patients with CD4+ cell counts below 100 céls/mm3. 
  • Effect of CCR5 inhibitors on human T cell homeostasis (in vitro studies and participation in DIS-MVC clinical trial).
  • Immunologic follow-up of pathogenic groups of interest: primoinfected HIV patients, LTNP, controllers, exposed uninfected.

Related Assets

Members

Montserrat Plana Prades
Alberto Crespo Guardo
Mª José Maleno

Related Assets

Related Assets

Publications

  • Therapeutic Dendritic Cell Vaccine in Chronic HIV-1 Infected Patients Receiving Antiretroviral Therapy (Therapeutic dendritic cell vaccine for HIV-1 infection) 
    García F, Climent N, Guardo AC, Gil C, León A, Autran B, Lifson J-D, Picado J-M, Dalmau J, Clotet B, Gatell J-M, Plana M, Gallart T for DCV2/MANON07-ORVACS study group  Science Translational Medicine. 2012 (accepted) 
  • Generation and characterization of a defective HIV-1 virus as an immunogen for a therapeutic vaccine. 
    Álvarez-Fernández C, Guardo AC, García-Pérez J, García F, Blanco J, Escribà-García L, Gatell JM, Alcami J, Plana M and Sánchez-Palomino S.  PLoS One. 2012 (accepted) 
  • In Vitro Effects Of CCR5 Inhibitor Maraviroc On Human T Cell Function. 
    Arberas H, Guardo AC, Bargalló ME, Maleno MJ, Calvo M, Blanco JL, García F, Gatell JM, Plana M.  J. Antimicrob. Chemoterapy. 2012 (accepted) 
  • Opportunistic infections and Immune Reconstitution Inflammatory Syndrome in the Combined Antiretroviral Therapy era: A comprehensive review. 
    Manzardo C, Guardo A-C, Letang E, Plana M, Gatell  J-M and Miro JM 2012 European Infectious Diseases (review) (accepted) 
  • Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection. 
    Hamlyn E, Hickling S, Porter K, Frater J, Phillips R, Robinson M, Mackie NE, Kaye S, McClure M, Fidler S; SPARTAC Investigators.  AIDS. 2012 Apr 24;26(7):887-90. 
  • Reasons for not participating in a phase I preventive HIV vaccine study in a resource rich country. 
    Lucero MC, Diaz-Brito V, Torres Murillo B, Corral Carretero S, Sala M, Casadesús C, Conde M, Jimenez JL, Pich J, Arnaiz JA, Leon A, Perez I, Muñoz-Fernández MA, Gatell JM, Plana M, Esteban M, Bernaldo de Quiros J, Garcia F.  AIDS Patient Care and STDs 26 (7): 379-382 JUL 2012 (Letter to the Editor) 
  • Therapeutic Dendritic Cell Vaccine in Chronic HIV-1 Infected Patients Receiving Antiretroviral Therapy (Therapeutic dendritic cell vaccine for HIV-1 infection) 
    García F, Climent N, Guardo AC, Gil C, León A, Autran B, Lifson J-D, Picado J-M, Dalmau J, Clotet B, Gatell J-M, Plana M, Gallart T for DCV2/MANON07-ORVACS study group.  Science Translational Medicine. 2012 (accepted) 

Related Assets

Network